Sareum Inks Deal with Hebei to Develop AML Drugs
By Cornelia Zou
Wednesday, December 4, 2013
HONG KONG – A leading UK-based cancer drug developer and a Chinese university research institute have announced plans to work together to develop a new leukemia drug that may have a number of other uses.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.